WASHINGTON, July 2, 2015 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a
HETLIOZ® patent, number 9,060,995 ('995 patent), is now
listed in the U.S. Food and Drug
Administration publication Approved Drug Products With
Therapeutic Equivalence Evaluations, commonly known as the Orange
Book. The '995 patent was issued by the United States Patent
and Trademark Office on June 23rd, 2015 and expires in
January 2033. Prior to this newly listed '995 patent, the
HETLIOZ® Orange Book listed patents were the U.S. composition
of matter '529 patent and the '492 patent, expected to expire
in December 2022 (assuming receipt of the five year patent
term extension under the Hatch-Waxman Act) and January 2033, respectively.
About Vanda Pharmaceuticals Inc.
Vanda
Pharmaceuticals Inc. is a biopharmaceutical company focused on
the development and commercialization of products for the treatment
of central nervous system disorders. For more on Vanda, please
visit www.vandapharma.com.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this release are "forward-looking
statements" under the securities laws. Forward-looking statements
are based upon current expectations that involve risks, changes in
circumstances, assumptions and uncertainties. Important factors
that could cause actual results to differ materially from those
reflected in Vanda's forward-looking statements include, among
others, Vanda's assumptions regarding the life of the HETLIOZ®
patents and other factors that are described in the "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition
and Results of Operations" sections of Vanda's annual report on
Form 10-K for the fiscal year ended December
31, 2014 and quarterly report on Form 10-Q for the quarter
ended March 31, 2015, which are on
file with the SEC and available on the SEC's website at
www.sec.gov. In addition to the risks described above and in
Vanda's annual report on Form 10-K and quarterly reports on Form
10-Q, other unknown or unpredictable factors also could affect
Vanda's results. There can be no assurance that the actual results
or developments anticipated by Vanda will be realized or, even if
substantially realized, that they will have the expected
consequences to, or effects on, Vanda. Therefore, no assurance can
be given that the outcomes stated in such forward-looking
statements and estimates will be achieved.
Corporate Contact:
Jim
Kelly
Senior Vice President and Chief Financial
Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
Media Contact:
Laney Landsman
Vice President
Makovsky
(212) 508-9643
llandsman@makovsky.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/vanda-announces-listing-of-a-new-hetlioz-patent-in-the-fda-orange-book-300108112.html
SOURCE Vanda Pharmaceuticals Inc.